Aktienanalyse zu ASP Isotopes Inc. (ASPI)ASPIASP Isotopes Inc.

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. Its proprietary technologies, the Aerodynamic Separation Process and Quantum Enrichment technology, are designed to enable the production of isotopes used in several industries. Its initial focus is on the production and commercialization of enriched Carbon-14 (C-14), Silicon-28 (Si-28) and Ytterbium-176 (Yb-176). It is also a provider of liquid helium with operations at the Virginia Gas Project in South Africa. Its nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate isotopes for highly specialized target end markets. It operates in the Healthcare sector (MISCELLANEOUS CHEMICAL PRODUCTS industry).

Currently, ASP Isotopes Inc is not a strong buy. The stock is priced at $3.88, which is significantly down 55.25% over the past year. The RSI is at 39.43, indicating it is nearing oversold territory, but the forward P/E ratio is very high at 54.35, suggesting that the stock may be overvalued based on future earnings expectations. Additionally, the company reported a net income loss of $33,993,000 in Q2 2026, which raises concerns about profitability. The main risk is the high forward P/E ratio, indicating potential overvaluation in the current market context.